Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of SR57667B in early Parkinson's disease
2004-001330-16Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing SR57667B 4 mg/day with Placebo (2 arms). Primary endpoint: Change in nigrostriatal dopaminergic function on 18F-Dopa PET. Started Sep 2004; status: completed.
02
Drugs
paliroden
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2004-001330-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001330-16.